c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 136 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Rilotumumab
CAS:<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Cor e Forma:LiquidPeso molecular:145.2 kDaCSF1R-IN-2
CAS:<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Fórmula:C20H20FN7O2Pureza:99.29%Cor e Forma:SolidPeso molecular:409.42Bozitinib
CAS:<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Fórmula:C20H15F3N8Pureza:99.16%Cor e Forma:SolidPeso molecular:424.38c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Fórmula:C17H14N8SPureza:98.77%Cor e Forma:SolidPeso molecular:362.41JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Cor e Forma:SolidPeso molecular:374.35Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Cor e Forma:SolidPeso molecular:518.56Emibetuzumab
CAS:<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Pureza:SDS-PAGE:96.2%;SEC-HPLC:98.8%Cor e Forma:LiquidPeso molecular:143.74 kDaSU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Fórmula:C13H8ClNOSPureza:98.84%Cor e Forma:SoildPeso molecular:261.73Onartuzumab
CAS:<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Pureza:97.3%Cor e Forma:LiquidPeso molecular:146.99 kDac-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Cor e Forma:Odour SolidPROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Fórmula:C51H50F2N6O13Peso molecular:992.97c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Fórmula:C16H13N7OPeso molecular:319.11816PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Fórmula:C45H41FN10O5Cor e Forma:SolidPeso molecular:820.87PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Cor e Forma:SolidPeso molecular:919.037Norleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Fórmula:C41H58N8O7Pureza:98%Cor e Forma:SolidPeso molecular:774.95LMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Fórmula:C18H11F3N4OPureza:99.89%Cor e Forma:SoildPeso molecular:356.3BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.56%Cor e Forma:SolidPeso molecular:512.89Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69Umikibart
Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.Cor e Forma:Odour Liquid
